Page 324 - ebook HCC

PROGRAMME AND ABSTRACTSAND ABSTRACTS
322
322 PROGRAMME GENEVA, SWITZERLAND EASL HCC SUMMIT 323
FEBRUARY 13 - 16, 2014

Poster Board Number C84

HEPATOCELLULAR CARCINOMA SCREENING NOTES
IS INDICATED EVEN AFTER SUSTAINED
VIROLOGICAL RESPONSE: -MOROCCAN
UNIVERSITY HOSPITAL EXPERIENCE-

Younès Cherradi, Rajaa Afifi , Hanaa Benbrahim , Wafaa Essamri ,
1
1
1
Imane Benelbarhdadi , Fatima Zahra Ajana, Omar Hadj El Malki ,
2
1
Mustapha Benazzouz, Abdellah Essaid
1 Department of Hepatogastroenterology Médecine “C”, Ibn Sina Hospital.,
2 Biostatistic, clinical and epidemiological research laboratory,
Mohammed V university- Souissi, Rabat, Morocco
Corresponding author’s e-mail: Cherradiyounes@hotmail.com
Introduction: In Morocco, Hepatitis C virus (HCV) infection is the first major cause
for hepatocellular carcinoma (HCC). Antiviral treatment limits fibrosis progression and
reduces the risk of developing liver cancer but few cases of HCC in treated HVC-carriers
had been reported.
Aims: The aim of this study is to define predictive factors and highly risk groups for
developing HCC.

Methodology: it’s a retroprospective and analytic study. It concerns all HCV carriers who
developed HCC after antiviral treatment. We compare HCV-treated patients who didn’t
develop HCC to patients with HCC. We used khi-2 and Ficher Exact analysis.
Results: Three hundred sixty nine HVC-treated patients were considered from January
CLINICAL POSTER ABSTRACTS years. Fifty Three percent of patients had genotype 1 HCV, 47% had genotype 2 HCV. CLINICAL POSTER ABSTRACTS
2002 to April 2010. Twenty HCC were reported with 12 female (60%) and 8 male (40%).
The mean age was 61 years old [40- 72]. The mean time of HCC occurrence is 5 +/-2
Severe fibrosis was reported in 94.6% at the beginning of treatment. The risk of HCC
was not significant according to gender and genotypes (respectively p= 0.63 and p=0.87).
Advanced age and severe fibrosis were significant risk factors (respectively p=0.003 and
p= 0. 0001). The comparison of sustained virological responders to patients who didn’t
achieve sustained virological response (SVR) shows significant
Results: HCC was reported in 2.6% of the first group vs. 12.5% of non-responders
(p=0.004) which demonstrates that SVR reduces significantly the risk of developing HCC.

Conclusion: In our series, 5% of previously treated patients developed an HCC. Advanced
age and severe fibrosis (F>2) at HCV diagnosis are predictive factors of HCC occurrence. SVR
reduces considerably the risk of HCC occurrence but screening is indicated even after SVR.